Type 2 DM Pharmacotherapy Selection Update and Management Considerations for Older Adults: Key updates related to T2DM pharmacotherapy from the 2023 ADA guideline include the following: Further emphasis for selecting pharmacotherapy (first-line and add-on therapies) based upon patient specific factors, comorbidities, and treatment goals (e.g., cardiorenal risk reduction in high-risk patients, glycemic and weight management, access, etc.)
Exenatide has a minimal effect on postlunch and overnight blood glucose control due to its short-acting pharmacokinetics (Fig
Novinscak T, Brcic L, Staresinic M, et al
Insurance coverage remains inconsistent, and out-of-pocket costs for branded versions exceed $1,000 monthly for many patients, creating an affordability crisis even when medications are in stock
The label says the product contains benzyl alcohol and aluminum
DHXA & TE50 is a laboratory-grade research chemical provided as a high-purity powder